FIDELIO-DKD
2020
Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease
In 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.
Result
Efficacy: Kidney failure, ≥40% eGFR decline, or renal deathHR 0.82 (95% CI 0.73-0.93) · P = 0.001
Below 1 favours finerenone, above 1 favours placebo.
- Absolute difference
- 3.3 points
- NNT
- 31
Absolute difference and NNT are derived from the event rates.
- Subtopic
- Nonsteroidal MRA
- Design
- Double-blind RCT, median 2.6-year follow-up
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Bakris GL, et al. N Engl J Med. 2020;383(23):2219-2229.doi 10.1056/NEJMoa2025845
Discussion & critique
Established the nonsteroidal MRA as renoprotective; hyperkalaemia-related discontinuation 2.3% vs 0.9%.